Her-2: The development of Herceptin, a revolutionary breast cancer treatment

What story does this book tell?

Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer, written by science journalist Robert Bazell, narrates the exciting scientific and human journey that led to the development of one of the most innovative treatments for breast cancer: Herceptin (trastuzumab). This book, classified in the health and breast cancer category, offers a deep look into the research that revolutionized oncology by focusing on the HER2 gene and its role in some aggressive types of breast cancer.

The science behind Herceptin

The book explains how scientists identified HER2 gene amplification as a key factor in certain breast cancers and how they developed a monoclonal antibody capable of blocking its action. This targeted therapy approach marked a before and after in treatment, offering hope to patients with HER2-positive breast cancer, who previously had a more reserved prognosis. Bazell's work breaks down the technical challenges and decisions that led to the drug's approval.

Why is it important to know about the development of Herceptin?

Understanding how Herceptin came about is not only relevant for health professionals, but also for patients and family members who want to know about the advances that have improved survival. The book shows the collaboration between researchers, the pharmaceutical industry, and clinical trials that allowed a revolutionary treatment to reach those who needed it. In addition, it raises ethical questions about access to innovation and the cost of oncological drugs.

Who is this book for?

This volume is aimed at readers interested in the history of medicine, breast cancer patients who want to better understand their treatment, and health science students looking for an inspiring narrative about scientific progress. Written in accessible language, it avoids excessive technicalities without sacrificing rigor. According to the categorization, it can be of great interest to those seeking information on breast cancer from a historical and scientific perspective.

Book content and structure

The work is organized into chapters that follow the timeline of the discovery of the HER2 gene, the first trials with monoclonal antibodies, and the path to Herceptin's approval by regulatory authorities. It includes interviews with the protagonists of this story, such as scientists Dennis Slamon and Axel Ullrich, and recounts the key moments that led to a paradigm shift in oncology. The book also addresses controversies surrounding clinical trials and the role of patients in research.

Frequently asked questions about this book

Is medical knowledge necessary to read it?
No, the author presents scientific concepts clearly and entertainingly, suitable for the general public.

Does the book include updated information about Herceptin?
Originally published in 1998, the book focuses on the initial development; however, the historical context remains valuable for understanding the fundamentals of targeted therapy.

Can this book help newly diagnosed patients?
Yes, it can offer a hopeful and educational insight into how one of the most emblematic treatments for breast cancer works.